“We are very pleased to collaborate in this important study with Merck, an established leader in cancer immunotherapy, with our first clinical asset, CUE-101, which represents our IL-2 variant CUE-100 Series,” said Daniel Passeri, chief executive officer of Cue Biopharma. “Through the monotherapy and combination studies, we believe we will be able to demonstrate the mechanistic advantages of our approach and platform for modulating disease-relevant T cells directly in the patient’s body to safely enhance efficacy over current standards of care.”“Immunotherapies have revolutionized the treatment of patients with certain types of cancers. However significant unmet need remains – particularly in those individuals who do not respond or develop resistance to checkpoint therapy,” said Ken Pienta, M.D, acting chief medical officer of Cue Biopharma. “Based on a novel mechanism of action designed to induce and expand tumor-specific T cells in the patient’s body, we believe CUE-101 may lead to enhanced anti-tumor activity in combination with KEYTRUDA.”. The article titled, CUE-101, a Novel HPV16 E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies, includes CUE-101 data that demonstrate selective binding, activation and expansion of HPV16-specific, disease-relevant, T cells.
1 other references
Cue Biopharma Announces Clinical Trial Collaboration Agreement with Merck to Evaluate CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment For HPV+ Recurrent/Metastatic Head and Neck CancerPublished on 20/04/2020 12:58 by: pipelinereview.com
Latest Stories From Referenced Companies
Meningitis Vaccine Market 2020: Industry Analysis, Size, Share, Trends, Key Companies (GlaxoSmithKline, Baxter International, Sanofi Pasteur, Merck, More) and Forecasts 2025 – Cole of Duty
Jul 15, 2020
Nanopharmaceuticals Market 2025 Insights Analysis and 23 Company Profiles (Merck, Pfizer, Novartis, Abbott, More) – Cole of Duty
Jul 14, 2020